BRPI0907641A2 - Piridinas fundidas ativas como inibidores de c-met - Google Patents
Piridinas fundidas ativas como inibidores de c-metInfo
- Publication number
- BRPI0907641A2 BRPI0907641A2 BRPI0907641-7A BRPI0907641A BRPI0907641A2 BR PI0907641 A2 BRPI0907641 A2 BR PI0907641A2 BR PI0907641 A BRPI0907641 A BR PI0907641A BR PI0907641 A2 BRPI0907641 A2 BR PI0907641A2
- Authority
- BR
- Brazil
- Prior art keywords
- met inhibitors
- fused pyridines
- active fused
- active
- pyridines
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0801416.9A GB0801416D0 (en) | 2008-01-25 | 2008-01-25 | Pharmaceutical compounds |
| PCT/GB2009/000211 WO2009093049A1 (en) | 2008-01-25 | 2009-01-26 | Fused pyridines active as inhibitors of c-met |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0907641A2 true BRPI0907641A2 (pt) | 2015-07-21 |
Family
ID=39186355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0907641-7A BRPI0907641A2 (pt) | 2008-01-25 | 2009-01-26 | Piridinas fundidas ativas como inibidores de c-met |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110053935A1 (pt) |
| EP (1) | EP2247584A1 (pt) |
| JP (1) | JP2011510058A (pt) |
| KR (1) | KR20100110344A (pt) |
| CN (1) | CN102015678A (pt) |
| AU (1) | AU2009207421A1 (pt) |
| BR (1) | BRPI0907641A2 (pt) |
| CA (1) | CA2712791A1 (pt) |
| GB (1) | GB0801416D0 (pt) |
| IL (1) | IL206930A0 (pt) |
| MX (1) | MX2010007714A (pt) |
| WO (1) | WO2009093049A1 (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2740746A1 (en) | 2008-10-14 | 2010-04-22 | Ning Xi | Compounds comprising a spiro-ring and and methods of use |
| EP2408300B1 (en) | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| EP2332939A1 (en) * | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| JP2013532627A (ja) | 2010-07-01 | 2013-08-19 | 武田薬品工業株式会社 | ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ |
| WO2012122011A2 (en) | 2011-03-04 | 2012-09-13 | Glaxosmithkline Llc | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| CN104968345B (zh) * | 2012-01-19 | 2018-05-08 | 肿瘤疗法科学股份有限公司 | 1,5-萘啶衍生物和含1,5-萘啶衍生物的melk抑制剂 |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
| JP6412503B2 (ja) | 2012-11-21 | 2018-10-24 | ピーティーシー セラピューティクス， インコーポレイテッド | 置換逆ピリミジンＢｍｉ−１阻害剤 |
| TWI630203B (zh) | 2013-02-21 | 2018-07-21 | 葛蘭素史克智慧財產發展有限公司 | 做為激酶抑制劑的喹唑啉類 |
| CN103467374A (zh) * | 2013-08-30 | 2013-12-25 | 江苏弘和药物研发有限公司 | 一种8-溴-4-羧基喹啉的合成方法 |
| KR102232595B1 (ko) * | 2013-08-30 | 2021-03-26 | 피티씨 테라퓨틱스, 인크. | 치환된 피리미딘 bmi-1 저해제 |
| EP3071553A4 (en) | 2013-11-21 | 2017-08-02 | PTC Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
| CN103694145B (zh) * | 2013-11-28 | 2016-02-10 | 山东鑫泉医药有限公司 | （2-甲基-5-硝基苯基）胍硫酸盐的合成方法 |
| EP3229836B1 (en) | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| CN105566313A (zh) * | 2016-03-22 | 2016-05-11 | 陕西思尔生物科技有限公司 | 头孢洛林酯中间体4-(4’-吡啶)-1,3-噻唑-2-硫醇的合成方法 |
| CN107573264A (zh) * | 2017-08-14 | 2018-01-12 | 贵州大学 | 一种3‑氰基‑5‑甲氧基苯‑1‑磺酰氯的制备工艺 |
| JP2021535198A (ja) | 2018-08-17 | 2021-12-16 | ピーティーシー セラピューティクス， インコーポレイテッド | 膵臓癌を治療する方法 |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN112759536A (zh) * | 2019-11-05 | 2021-05-07 | 常州锐博生物科技有限公司 | 取代的苯磺酰氯的制备方法 |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN114605391B (zh) * | 2022-02-21 | 2024-01-26 | 广州六顺生物科技股份有限公司 | 喹喔啉类衍生物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4310109B2 (ja) * | 2001-04-26 | 2009-08-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物 |
| AU2005245386B2 (en) * | 2004-05-07 | 2008-11-27 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| KR20080016659A (ko) * | 2005-05-20 | 2008-02-21 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로서 유용한 피롤로피리딘 |
| US7868177B2 (en) * | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| TW200815429A (en) * | 2006-04-11 | 2008-04-01 | Smithkline Beecham Corp | Thiazolidinedione derivatives as PI3 kinase inhibitors |
| TW200825054A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
-
2008
- 2008-01-25 GB GBGB0801416.9A patent/GB0801416D0/en not_active Ceased
-
2009
- 2009-01-26 AU AU2009207421A patent/AU2009207421A1/en not_active Abandoned
- 2009-01-26 WO PCT/GB2009/000211 patent/WO2009093049A1/en not_active Ceased
- 2009-01-26 KR KR1020107016733A patent/KR20100110344A/ko not_active Withdrawn
- 2009-01-26 EP EP09704615A patent/EP2247584A1/en not_active Withdrawn
- 2009-01-26 MX MX2010007714A patent/MX2010007714A/es not_active Application Discontinuation
- 2009-01-26 US US12/864,112 patent/US20110053935A1/en not_active Abandoned
- 2009-01-26 BR BRPI0907641-7A patent/BRPI0907641A2/pt not_active IP Right Cessation
- 2009-01-26 CN CN2009801113771A patent/CN102015678A/zh active Pending
- 2009-01-26 CA CA2712791A patent/CA2712791A1/en not_active Abandoned
- 2009-01-26 JP JP2010543574A patent/JP2011510058A/ja active Pending
-
2010
- 2010-07-11 IL IL206930A patent/IL206930A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011510058A (ja) | 2011-03-31 |
| US20110053935A1 (en) | 2011-03-03 |
| GB0801416D0 (en) | 2008-03-05 |
| WO2009093049A1 (en) | 2009-07-30 |
| MX2010007714A (es) | 2010-08-09 |
| CA2712791A1 (en) | 2009-07-30 |
| CN102015678A (zh) | 2011-04-13 |
| AU2009207421A1 (en) | 2009-07-30 |
| KR20100110344A (ko) | 2010-10-12 |
| EP2247584A1 (en) | 2010-11-10 |
| IL206930A0 (en) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20250007I1 (fi) | Fidanakogeenielaparvoveekki | |
| IL206930A0 (en) | Fused pyridines active as inhibitors of c-met | |
| BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
| PT2528897E (pt) | Derivados de piridina dissubstituída como anticancerígenos | |
| BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
| PT2860179T (pt) | Derivados de pirazolo-piridina como inibidores de nadph-oxidase | |
| BRPI0810462A2 (pt) | Derivados de quinolina-carboxamida como antagonistas de p2y12 | |
| BR112012000763A2 (pt) | derivados de piridin-4-ila | |
| BRPI1013821A2 (pt) | piridinas substituídas como antagonistas de ccr3. | |
| BRPI0913580A2 (pt) | pirrolopiridinas como inibidores de quinase | |
| EP2320221A4 (en) | ELECTRODE | |
| BRPI0922845A2 (pt) | pirazol-4-n-alcoxicarboxamidas como microbiocidas | |
| EP2346734A4 (en) | ACTIVE WINGLET | |
| BRPI0914895A2 (pt) | artigo absorvente | |
| BRPI0918372A2 (pt) | artigo absorvente | |
| BRPI0820241A2 (pt) | artigo absorvente | |
| BRPI0821175A2 (pt) | artigo absorvente | |
| BRPI0914657A2 (pt) | piridin-2-onae piridazin-3-onas substituídas | |
| BRPI0911444A2 (pt) | benzoimidazóis como inibidores de prolil hidroxilase | |
| ES2598358T8 (es) | Derivados de quinolina como inhibidores de PI3K quinasa | |
| BRPI0911347A2 (pt) | gama lactamas substituídas como agentes terapêuticos | |
| BR112013015449A2 (pt) | compostos de bi-heteroarila como inibidores de vps23 | |
| DK2246017T3 (da) | Absorberende genstand | |
| CR20130403A (es) | Derivados de fluoro-piridinona útiles como agentes antibacterianos | |
| BRPI0920239A2 (pt) | compostos heterocíclicos como inibidores de proteínas quinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |